We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.66 | 1.95% | 86.89 | 85.85 | 87.00 | 86.98 | 85.07 | 85.27 | 1,871,390 | 16:40:00 |
From Apr 2022 to Apr 2024
By Maitane Sardon
Sanofi SA said Monday that the Covid-19 booster vaccine it is developing with U.K. drug company GlaxoSmithKline has shown strong immune response in vaccinated adults in a Phase 3 trial.
The French pharma company said the jointly produced next-generation booster has potential to protect against multiple variants, including Omicron BA.1 and BA.2.
The company also said that another trial has shown that, in adults with two doses of the Pfizer-BioNTech Comirnaty vaccine, the Sanofi-GSK booster generated a higher immune response than the Pfizer-BioNTech's booster.
Write to Maitane Sardon at maitane.sardon@wsj.com
(END) Dow Jones Newswires
June 13, 2022 02:28 ET (06:28 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
